Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737727 | 0.80 | CHEK1 (0.32) | CHEK1FLT3PLK3 | |
| SCHEMBL14737661 | 0.76 | CHEK1 (0.35) | CHEK1FLT3PLK3 | |
| SCHEMBL5746944 | 0.68 | CHEK1 (0.46) | CHEK1FLT3PLK3 | |
| SCHEMBL30039348 | 0.66 | KDM4E (0.53) | CHEK1FLT3PLK3 | |
| SCHEMBL5484683 | 0.66 | KDM4E (0.53) | CHEK1FLT3PLK3 | |
| SCHEMBL25045526 | 0.66 | CHEK1 (0.42) | CHEK1FLT3PLK3 | |
| SCHEMBL15866141 | 0.65 | CHEK1 (0.66) | CHEK1FLT3PLK3 | |
| SCHEMBL30040295 | 0.65 | CHEK1 (0.66) | CHEK1FLT3PLK3 | |
| SCHEMBL14158301 | 0.63 | CHEK1 (0.40) | CHEK1FLT3PLK3 | |
| SCHEMBL21549431 | 0.63 | CHEK1 (0.40) | CHEK1FLT3PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| CN-104024258-B | Pyrrolopyrazine kinase inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | CHEK1 1685/4885FLT3 49/4885PLK3 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.